Table 1.

Primary tumor and treatment characteristics.

Patient	Age at initial diagnosis (years)	Histology of primary disease	Subtype	Prior radiation details	Prior adjuvant therapy
1	53	IDC	ER/PR+	WBI 50 and 15 Gy boost	CMF, tamoxifen
2	38	Hodgkin’s lymphoma	–	Mantle field 40 Gy	–
3	44	DCIS	ER/PR+	WBI dose unknown	Tamoxifen
4	76	IDC	ER/PR+	WBI dose unknown	Anastrazole started but did not tolerate
5	49	DCIS	ER/PR+	WBI 50 and 15 Gy boost	None
6	52	NSCLC	–	Right lung and mediastinum IMRT 66 Gyb	–
7	43	IDC	TNBC	WBI 50.4 and 10 Gy boost	ddAC
8	20	Hodgkin’s lymphoma	–	Mantle field 40 Gy	–
9	53	DCIS	ER/PR−	WBI 50.4 and 10 Gy boost	None
10	51	IDC	ER/PR+	WBI, 50.4 and 12 Gy boosta	A/T/bevacizumab/lupronb
11	59	IDC	ER/PR+	WBI dose unknown	Tamoxifen
12	54	IDC	ER/PR+	WBI dose unknown	None

IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; NSCLC, non-small cell lung cancer; IMRT, intensity modulated radiation therapy; CMF, cyclophosphamide, methotrexate, fluorouracil; ddAC, dose dense doxorubicin, cyclophosphamide; AT, doxorubicin, paclitaxel.

^aPatient was treated with neoadjuvant chemotherapy and definitive radiation therapy for her initial primary. ^bTherapy given in the neoadjuvant setting.

^bRight breast mean dose 10.9 Gy, max point dose 59.6 Gy.